Ashton Thomas Private Wealth LLC Boosts Position in Lantheus Holdings, Inc. $LNTH

Ashton Thomas Private Wealth LLC raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 68.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 21,312 shares of the medical equipment provider’s stock after purchasing an additional 8,632 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Lantheus were worth $1,093,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in LNTH. Janney Montgomery Scott LLC grew its stake in Lantheus by 17.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 31,388 shares of the medical equipment provider’s stock valued at $2,569,000 after acquiring an additional 4,677 shares during the last quarter. Truist Financial Corp lifted its holdings in shares of Lantheus by 6.1% in the second quarter. Truist Financial Corp now owns 6,696 shares of the medical equipment provider’s stock valued at $548,000 after purchasing an additional 382 shares in the last quarter. KLP Kapitalforvaltning AS lifted its holdings in shares of Lantheus by 12.5% in the second quarter. KLP Kapitalforvaltning AS now owns 26,023 shares of the medical equipment provider’s stock valued at $2,130,000 after purchasing an additional 2,900 shares in the last quarter. Galvin Gaustad & Stein LLC acquired a new stake in shares of Lantheus in the second quarter valued at approximately $11,899,000. Finally, MGO One Seven LLC purchased a new position in shares of Lantheus during the 2nd quarter worth approximately $274,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LNTH shares. Truist Financial upped their target price on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Finally, Mizuho increased their price objective on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average target price of $78.00.

Lantheus Trading Up 0.0%

Shares of LNTH opened at $64.89 on Friday. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The company has a market capitalization of $4.30 billion, a PE ratio of 27.26 and a beta of -0.08. The stock has a fifty day moving average of $65.59 and a two-hundred day moving average of $59.73. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 EPS for the quarter, meeting the consensus estimate of $1.27. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The firm had revenue of $384.01 million during the quarter, compared to analyst estimates of $363.42 million. During the same period in the prior year, the firm posted $1.70 earnings per share. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. As a group, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.